Compile Data Set for Download or QSAR
Report error Found 1957 for UniProtKB: Q02108
TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281728((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  22nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281729((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  89nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281730(US10023528, Example 4 | US10023528, Example 3 | US...)
Affinity DataEC50:  37nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281730(US10023528, Example 4 | US10023528, Example 3 | US...)
Affinity DataEC50:  110nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281732(US10023528, Example 5 | US10023528, Example 6 | US...)
Affinity DataEC50:  5.20nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281732(US10023528, Example 5 | US10023528, Example 6 | US...)
Affinity DataEC50:  56nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281734(US10023528, Example 10 | US10259776, Example 10)
Affinity DataEC50:  10nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281735(US10023528, Example 12 | US10259776, Example 12)
Affinity DataEC50:  17nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281736(US10023528, Example 13 | US10259776, Example 13)
Affinity DataEC50:  14nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281737(US10023528, Example 14 | US10259776, Example 14)
Affinity DataEC50:  8.40nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281738((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  68nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281739(US10023528, Example 25 | US10259776, Example 25)
Affinity DataEC50:  220nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281740(US10023528, Example 27 | US10259776, Example 27)
Affinity DataEC50:  68nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281741(3-(4-Chloro-3-{[(3R)-2-chlorophenyl)-4,4,4-trifluo...)
Affinity DataEC50:  640nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281742((+)-3-(4-Chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4...)
Affinity DataEC50:  11nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM281743(US10023528, Example 35 | US10259776, Example 35)
Affinity DataEC50:  11nMpH: 7.5 T: 2°CAssay Description:To carry out the assay, 29 μl of enzyme solution [0-10 nM soluble guanylate cyclase (prepared according to H nicka et al, J. Mol. Med. 77, 14-23...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321477(US10183021, Compound I-3)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321478(US10183021, Compound I-200)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321479(US10183021, Compound I-4)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321480(US10183021, Compound I-204)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321481(US10183021, Compound I-11)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321482(US10183021, Compound I-206)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321483(US10183021, Compound I-14)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321484(US10183021, Compound I-213)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321485(US10183021, Compound I-16)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321486(US10183021, Compound I-214)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321487(US10183021, Compound I-19)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321488(US10183021, Compound I-219)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321489(US10183021, Compound I-24)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321490(US10183021, Compound I-221)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321491(US10183021, Compound I-35)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321492(US10183021, Compound I-230)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321493(US10183021, Compound I-39)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321494(US10183021, Compound I-236)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321495(US10183021, Compound I-41)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321496(US10183021, Compound I-239)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321497(US10183021, Compound I-53)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321498(US10183021, Compound I-245)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321499(US10183021, Compound I-54)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321500(US10183021, Compound I-187)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321501(US10183021, Compound I-55)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321502(US10183021, Compound I-300)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321503(US10183021, Compound I-59)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321504(US10183021, Compound I-250)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321505(US10183021, Compound I-67)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321506(US10183021, Compound I-306)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321507(US10183021, Compound I-69)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321508(US10183021, Compound I-453)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321509(US10183021, Compound I-81)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetGuanylate cyclase soluble subunit alpha-1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM321510(US10183021, Compound I-361)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1957 total ) | Next | Last >>
Jump to: